Literature DB >> 22014257

A case series of buprenorphine/naloxone treatment in a primary care practice.

Benjamin Doolittle1, William Becker.   

Abstract

Physicians' adoption of buprenorphine/naloxone treatment is hindered by concerns over feasibility, cost, and lack of comfort treating patients with addiction. We examined the use of buprenorphine/naloxone in a community practice by two generalist physicians without addiction training, employing a retrospective chart review. From 2006-2010, 228 patients with opiate abuse/dependence were treated with buprenorphine/naloxone using a home-induction protocol. Multiple co-morbidities including diabetes (23% of patients), hypertension (36%), Hepatitis C (43%), and depression (74%) were concurrently managed. In this diverse sample, 1/228 experienced precipitated withdrawal during induction. Of the convenience subsample analyzed (n = 28), 82% (+/-10%) had negative urine drug tests for opioids; 92% (+/-11%) were negative for cocaine; 88% (+/-12%) were positive for buprenorphine. This case series demonstrated feasibility and safety of a low-cost buprenorphine/naloxone home induction protocol employed by generalists. Concurrent treatment of multiple comorbidities conforms with the patient-centered medical home ideal. Randomized trials of this promising approach are needed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014257     DOI: 10.1080/08897077.2011.599256

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  10 in total

1.  A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy.

Authors:  Yatan Pal Singh Balhara; Raka Jain
Journal:  Innov Clin Neurosci       Date:  2012-07

2.  Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.

Authors:  Dinah Kanate; David Folk; Sharon Cirone; Janet Gordon; Mike Kirlew; Terri Veale; Natalie Bocking; Sara Rea; Len Kelly
Journal:  Can Fam Physician       Date:  2015-02       Impact factor: 3.275

3.  Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.

Authors:  Cindy Xinxin Du; Julia Shi; Jeanette M Tetrault; Lynn M Madden; Declan T Barry
Journal:  Fam Pract       Date:  2022-03-24       Impact factor: 2.267

4.  Patient predictors of substance use disorder treatment initiation in primary care.

Authors:  Allison J Ober; Katherine E Watkins; Colleen M McCullough; Claude M Setodji; Karen Osilla; Sarah B Hunter
Journal:  J Subst Abuse Treat       Date:  2018-04-28

5.  An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol.

Authors:  Allison J Ober; Katherine E Watkins; Sarah B Hunter; Karen Lamp; Mimi Lind; Claude M Setodji
Journal:  Implement Sci       Date:  2015-05-08       Impact factor: 7.327

6.  Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States.

Authors:  Valerie E Whiteman; Jason L Salemi; Mulubrhan F Mogos; Mary Ashley Cain; Muktar H Aliyu; Hamisu M Salihu
Journal:  J Pregnancy       Date:  2014-08-28

Review 7.  Primary care models for treating opioid use disorders: What actually works? A systematic review.

Authors:  Pooja Lagisetty; Katarzyna Klasa; Christopher Bush; Michele Heisler; Vineet Chopra; Amy Bohnert
Journal:  PLoS One       Date:  2017-10-17       Impact factor: 3.240

8.  Sustaining alcohol and opioid use disorder treatment in primary care: a mixed methods study.

Authors:  Sarah B Hunter; Allison J Ober; Colleen M McCullough; Erik D Storholm; Praise O Iyiewuare; Chau Pham; Katherine E Watkins
Journal:  Implement Sci       Date:  2018-06-18       Impact factor: 7.327

9.  Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.

Authors:  Theresa A Rowe; Janet S Jacapraro; Darius A Rastegar
Journal:  Addict Sci Clin Pract       Date:  2012-10-29

10.  Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.

Authors:  Allison J Ober; Katherine E Watkins; Sarah B Hunter; Brett Ewing; Karen Lamp; Mimi Lind; Kirsten Becker; Keith Heinzerling; Karen C Osilla; Allison L Diamant; Claude M Setodji
Journal:  BMC Fam Pract       Date:  2017-12-21       Impact factor: 2.497

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.